ArticleBrain tumor pathology2026
Histologically indolent but widely disseminated diffuse midline glioma H3K27-altered revealed by autopsy.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diffuse midline glioma, H3K27-altered is a highly aggressive central nervous system tumor classified as grade 4 in the 2021 World Health Organization Classification of Tumors of the Central Nervous System. This malignancy typically arises in midline structures such as the thalamus, brainstem, and spinal cord, and is characterized by its infiltrative capacity. Despite the use of magnetic resonance imaging to evaluate tumor extension, its microscopic dissemination can extend far beyond radiological detection. We report the case of a 46-year-old woman with a thalamic diffuse midline glioma harboring an H3K27M mutation. She underwent endoscopic resection followed by standard radiotherapy and chemotherapy with temozolomide. Despite salvage treatments, she died 33 months after initial therapy. Autopsy revealed widespread microscopic infiltration involving the brainstem, cerebellum, and spinal meninges, extending from the cervical to lumbar regions. Notably, these lesions were not detected by MRI or routine histopathology. This case highlights the extensive infiltrative capacity of diffuse midline glioma with H3K27M mutation, demonstrating its ability to permeate central nervous system structures while preserving tissue architecture.
Indexed as
Identifiers
41495345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.